(Q39574170)

13 September 2017

1 reference

title

High-dose medroxyprogesterone acetate (MPA) treatment in advanced breast cancer. A review (English)

1 reference

13 September 2017

High-Dose Medroxyprogesterone Acetate (MPA) Treatment in Advanced Breast Cancer. A Review (English)

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

medroxyprogesterone acetate

19 April 2023

main subject

1 reference

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

19 April 2023

author name string

F. Ganzina

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A390798

19 April 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=390798

19 April 2023

publication date

1 October 1979

1 reference

13 September 2017

31 October 1979

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=390798

full work available at URL

19 April 2023

http://journals.sagepub.com/doi/pdf/10.1177/030089167906500507

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

19 April 2023

1 reference

13 September 2017

65

1 reference

13 September 2017

5

1 reference

13 September 2017

563-585

1 reference

On the Mechanism of the Anti-androgenic Effect of Medroxyprogesterone Acetate*

13 September 2017

1

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

MANAGEMENT OF ADVANCED ENDOMETRIAL ADENOCARCINOMA WITH MEDROXYPROGESTERONE ACETATE

19 April 2023

3

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

The possible mechanisms of action of progestins on endometrial adenocarcinoma.

19 April 2023

4

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

6α-Methyl-17α-HYDROXYPROGESTERONE 17-ACYLATES; A NEW CLASS OF POTENT PROGESTINS¹

19 April 2023

6

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Combined chemo- and hormonal therapy in advanced breast cancer

19 April 2023

10

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Oestrogen receptors and antagonism of steroid hormone action

19 April 2023

15

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Measurement of Medroxyprogesterone Acetate (Provera) by Radioimmunoassay1

19 April 2023

17

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Oestrogen receptors in human malignant melanoma

19 April 2023

26

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Effect of Medroxyprogesterone Acetate (Provera) on the Metabolism and Biological Activity of Testosterone

19 April 2023

27

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Clinical trial of Δ1-testololactone (NSC 23759), medroxy progesterone acetate (NSC 26386) and oxylone acetate (NSC 47438) in advanced female mammary cancer:A report of the cooperative breast cancer group

19 April 2023

28

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Estrogen metabolism in normal and neoplastic endometrium

19 April 2023

29

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

19 April 2023

31

32

233

Heuson J.C.

1972

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

MCF-7: A human breast cancer cell line with estrogen, androgen, progesterone, and glucocorticoid receptors

19 April 2023

35

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Progesterone antagonism of the oestrogen receptor and oestrogen-induced uterine growth

19 April 2023

36

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Control of Uterine Estrogen Receptor Levels by Progesterone

19 April 2023

37

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Rapid induction of mammary carcinoma in the rat and the influence of hormones on the tumors

19 April 2023

38

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Extinction of experimental mammary cancer. I. Estradiol-17beta and progesterone

19 April 2023

39

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Effects of progesterone on 9,10-dimethyl-1,2-benzanthracene-induced mammary tumours in Sprague-Dawley rats

19 April 2023

41

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Estrogen Receptor Assay in the Differential Diagnosis of Adenocarcinomas

19 April 2023

46

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

19 April 2023

Cancer Treatment Reports

47

60

251

Klaassen D.J.

1976

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Combination chemotherapy of germ cell tumors of the testis with vincristine, adriamycin, cyclophosphamide, actinomycin D and medroxyprogesterone acetate

19 April 2023

48

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Antiestrogens in the treatment of breast cancer

19 April 2023

53

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Glucocorticoid-binding proteins in human acute lymphoblastic leukemic blast cells

19 April 2023

54

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

19 April 2023

Cancer Treatment Reports

55

60

85

Mannes P.

1976

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Alcohol infusion of the pituitary, high-dose medroxyprogesterone and their association as analgesics in advanced breast cancer (author's transl)

19 April 2023

57

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Pituitary-adrenal function in ten patients receiving medroxyprogesterone acetate for true precocious puberty.

19 April 2023

59

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

A Role for Progesterone in Breast Cancer

19 April 2023

61

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Hormones in breast cancer: Update 1978

19 April 2023

63

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

The measurement of androgen receptors in human prostatic tissue utilizing sucrose density centrifugation and a protamine precipitation assay

19 April 2023

64

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Hormonal control of oestrogen receptor in uterus and receptivity for ovoimplantation in the rat

19 April 2023

65

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Treatment of breast cancer with medroxyprogesterone acetate

19 April 2023

66

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Survival and hormonal responsiveness of endometrial carcinoma in organ culture

19 April 2023

68

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Effect of progesterone on human endometrial carcinoma in different experimental systems

19 April 2023

69

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA

19 April 2023

70

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancer

19 April 2023

72

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

19 April 2023

Cancer Treatment Reports

75

62

499

Pannuti F.

1978

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Effect of treatment with medroxyprogesterone acetate (Provera) on testicular function

19 April 2023

80

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

High Dose Medroxyprogesterone Acetate (MPA) Treatment in Metastatic Carcinoma of the Breast: A Dose-Response Evaluation

19 April 2023

81

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project

19 April 2023

88

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Progestin therapy of breast cancer: comparison of agents

19 April 2023

89

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Anti-oestrogens and breast cancer

19 April 2023

92

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Target tissue receptors for progesterone: the influence of estrogen treatment

19 April 2023

93

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Estradiol and 20alpha-dihydroprogesterone dehydrogenase activities in human endometrium during the menstrual cycle

19 April 2023

95

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Induction of Human Endometrial Estradiol Dehydrogenase by Progestins

19 April 2023

96

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

Effects of progestins on estradiol receptor levels in human endometrium

19 April 2023

97

1 reference

https://api.crossref.org/works/10.1177/030089167906500507

19 April 2023

Identifiers

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=390798

19 April 2023

1 reference